These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 8093763)

  • 1. OSIRIS trial.
    Robertson B; Speer CP
    Lancet; 1993 Jan; 341(8838):172; author reply 173-4. PubMed ID: 8093763
    [No Abstract]   [Full Text] [Related]  

  • 2. OSIRIS trial.
    Morley C
    Lancet; 1993 Jan; 341(8838):172-3; author reply 173-4. PubMed ID: 8093764
    [No Abstract]   [Full Text] [Related]  

  • 3. OSIRIS trial.
    Gore SM
    Lancet; 1993 Jan; 341(8838):172; author reply 173-4. PubMed ID: 8093762
    [No Abstract]   [Full Text] [Related]  

  • 4. Surfactant for babies.
    Lancet; 1992 Dec; 340(8832):1387. PubMed ID: 1360097
    [No Abstract]   [Full Text] [Related]  

  • 5. Criteria for use of colfosceril (Exosurf) in neonates.
    Bhatt-Mehta V; Schumacher RE
    Clin Pharm; 1992 Apr; 11(4):355-7. PubMed ID: 1563234
    [No Abstract]   [Full Text] [Related]  

  • 6. Early versus delayed neonatal administration of a synthetic surfactant--the judgment of OSIRIS. The OSIRIS Collaborative Group (open study of infants at high risk of or with respiratory insufficiency--the role of surfactant.
    Lancet; 1992 Dec; 340(8832):1363-9. PubMed ID: 1360087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OSIRIS trial.
    Tarnow-Mordi W
    Lancet; 1993 Jan; 341(8838):174. PubMed ID: 8093765
    [No Abstract]   [Full Text] [Related]  

  • 8. Respiratory distress syndrome in New Zealand: evidence from the OSIRIS trial of exogenous surfactant (Exosurf).
    Wach R; Darlow B; Bourchier D; Broadbent R; Knight D; Selby R
    N Z Med J; 1994 Jun; 107(980):234-7. PubMed ID: 8208494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early or selective surfactant (colfosceril palmitate, Exosurf) for intubated babies at 26 to 29 weeks gestation. A European double-blind trial with sequential analysis. European Exosurf Study Group.
    Online J Curr Clin Trials; 1992 Nov; Doc No 28():[3886 words; 47 paragraphs]. PubMed ID: 1343614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Natural and synthetic surfactant in the treatment of neonatal respiratory distress syndrome].
    Bratlid D; Farstad T
    Tidsskr Nor Laegeforen; 1994 Jan; 114(1):33-6. PubMed ID: 8296279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the changes in the a/A oxygen ratio after administration of two surfactants for the treatment of neonatal respiratory distress syndrome.
    Bassiouny MR; Remo C; Cherian E
    J Trop Pediatr; 1997 Feb; 43(1):38-41. PubMed ID: 9078827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exosurf treatment investigational new drug phase: effect of an individualized third dose in infants with respiratory distress syndrome.
    Easa D; Pelke S; Nakamura KT; Barrett J; Balaraman V; Loo SW; Ibarra-Pratt E; Smith MB
    Pediatr Pulmonol; 1992 Sep; 14(1):16-22. PubMed ID: 1437338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Instillation rate effects of Exosurf on cerebral and cardiovascular haemodynamics in preterm neonates.
    Saliba E; Nashashibi M; Vaillant MC; Nasr C; Laugier J
    Arch Dis Child Fetal Neonatal Ed; 1994 Nov; 71(3):F174-8. PubMed ID: 7820712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing surfactant products.
    Prevost RR
    Clin Pharm; 1991 Dec; 10(12):909, 911. PubMed ID: 1773577
    [No Abstract]   [Full Text] [Related]  

  • 15. The instillated surfactant in the treatment of sepsis-induced ARDS: case report.
    Imperatore F; Postiglione M; Diurno F; Cirillo F; Liguori G; Pica M
    Intensive Care Med; 1999 Mar; 25(3):330-1. PubMed ID: 10229173
    [No Abstract]   [Full Text] [Related]  

  • 16. Colfosceril palmitate (Exosurf)--artificial surfactant for immature lungs.
    Drug Ther Bull; 1991 Jun; 29(12):46. PubMed ID: 1935584
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of two rescue doses of synthetic surfactant in 344 infants with respiratory distress syndrome weighing 750 to 1249 grams: a double-blind, placebo-controlled multicenter Canadian trial. Canadian Exosurf Neonatal Study Group.
    McMillan D; Chernick V; Finer N; Schiff D; Bard H; Watts J; Krzeski R; Long W
    J Pediatr; 1995 May; 126(5 Pt 2):S90-8. PubMed ID: 7745517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year follow-up of 89 infants with birth weights of 500 to 749 grams and respiratory distress syndrome randomized to two rescue doses of synthetic surfactant or air placebo. Canadian Exosurf Neonatal Study Group. Canadian Exosurf Neonatal Follow-Up Group.
    Casiro O; Bingham W; MacMurray B; Whitfield M; Saigal S; Vincer M; Long W
    J Pediatr; 1995 May; 126(5 Pt 2):S53-60. PubMed ID: 7745512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs and outcomes associated with colfosceril versus beractant for the treatment of neonatal respiratory distress syndrome.
    Wyble L; Santeiro ML
    Ann Pharmacother; 1997 Jun; 31(6):787-8. PubMed ID: 9184726
    [No Abstract]   [Full Text] [Related]  

  • 20. [Systemic and pulmonary hemodynamics in the course of substitute therapy with exosurf neonatal in newborn infants with respiratory distress syndrome].
    Milenin OB; Efimov MS
    Anesteziol Reanimatol; 1996; (6):7-10. PubMed ID: 9045592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.